Prostaglandin EP4 receptor
Ensembl | |||||||||
---|---|---|---|---|---|---|---|---|---|
UniProt | |||||||||
RefSeq (mRNA) | |||||||||
RefSeq (protein) | |||||||||
Location (UCSC) | Chr 5: 40.68 – 40.69 Mb | Chr 15: 5.24 – 5.27 Mb | |||||||
PubMed search | [3] | [4] |
View/Edit Human | View/Edit Mouse |
Prostaglandin E2 receptor 4 (EP4) is a
Gene
The PTGER4 gene is located on human chromosome 5p13.1 at position p13.1 (i.e. 5p13.1), contains 7 exons, and codes for a G protein-coupled receptor (GPCR) of the rhodopsin-like receptor family, Subfamily A14 (see rhodopsin-like receptors#Subfamily A14).[7] [8]
Expression
In humans,
Ligands
Activating ligands
Standard
Inhibiting ligands
Inhibitory receptor antagonists for EP4, including grapiprant (CJ-023,423), ONO-AE3-208, GW627368X, AH23848, and ONO-AE2-227, are in development for possible clinical use as inhibitors of the progression of prostate, breast, colon, and lung cancers.[13]
Mechanism of cell activation
EP4 is classified as a relaxant type of
Following its activation, EP4 undergoes
Functions
Studies using animals genetically engineered to lack EP4 and supplemented by studies examining the actions of EP4 receptor antagonists and agonists in animals as well as animal and human tissues indicate that this receptor serves various functions. However, an EP4 receptor function found in these studies does not necessarily indicate that in does so in humans since EP receptor functions can vary between species.[14]
Ductus arteriosus
EP4 plays a critical role in postnatal closure of the
To allow further studies of EP4 function, colonies obtained by cross-breeding the 5% of mice surviving EP4 deletion are used.[6]
Inflammation
Activation of EP4 suppresses the production of
Gastrointestinal tract
EP4 receptors are highly expressed in the small intestine and colon. Mice lacking this receptor or treated with a selective EP4 antagonist proved to be far more susceptible to the development of dextran sodium sulphate (DSS)-induced colitis and to be protected from developing the colitis by pre-treatment with EP4-selective agonists (ONO-AE1-734 and AGN205203). The DDS-inflicted lesions were associated with defective colon mucosa barrier function along with the overexpression of genes mediating inflammatory responses and under-expression of genes involved in mucosal repair and remodeling. EP4 thus appears to serve anti-inflammatory and protective functions in the colon and agonists of this receptor may be useful for treating inflammatory bowel diseases such as ulcerative colitis.[19] Activation of EP4 stimulates duodenum epithelial cells to secrete bicarbonate (HCO3-) in mice and humans; this response neutralizes the acidic fluid flowing from the stomach thereby contributing to the process of intestinal ulcer healing. Activators of this receptor therefore may useful as anti-ulcer drugs.[14]
Bone
Studies in mice found that the PGE2-EP4 pathway induces
Heart
In mice, EP4 receptor agonists reduce the acute rejection of transplanted hearts, prolong the survival of heart-transplanted animals, and reduce cardiac damage in a model of
Lipid metabolism
EP4 receptor-depleted mice exhibit slower weight gain; reduced adiposity upon high fat diet challenge; and shortened life span. These deficiencies are associated with disrupted lipid metabolism due to impaired triglyceride clearance; this impaired triglyceride clearance may underlie the cited deficiencies.[11][20]
Cancer
The EP4 receptor is over-expressed in human prostate cancer tissue and a selective EP4-receptor antagonist inhibits the growth and
Hearing
EP44 receptors are expressed in the cochlea of the inner ear. Pre- and post-treatment of guinea pigs with an EP4 agonist significantly attenuated threshold shifts of auditory brain stem responses and significantly reduced the loss of outer hair cells caused by prior noise exposure. These findings indicate that EP4 is involved in mechanisms for prostaglandin E(1) actions on the cochlea, and local EP4 agonist treatment may be a means for attenuating noise-induced hearing lose.[21][6]
Eye
A selective EP4 antagonists significantly reduced corneal neovascularization in rats caused by oxygen-induced retinopathy or laser-induced choroidal neovascularization. This result suggests that EP4 activation contributes to corneal neovascularization and that EP4 antagonists may be useful for treating neovascular eye disease.[6]
Clinical significance
Translational research
Clinical translational research studies using EP4 stimulators (i.e. agonists) or inhibitors (i.e. antagonists) that have been conducted or are underway include:
- The selective EP4 agonist, name
rivenprost (ONO-4819), improved the ulcerative colitis symptoms of 3 among 4 tested patients in a phase 2 clinical trial finished in 2009 (https://clinicaltrials.gov/ct2/show/record/NCT00296556?term=rivenprost&rank=10) but no follow-up studies have been recorded.[13] - The EP4 selective antagonist, CJ-023,423, was tested for its effectiveness in treating gastroduodenal ulcers in patients between 2006 and 2008 d with no results reported (https://clinicaltrials.gov/ct2/show/NCT00392080?term=CJ-023%2C423&rank=1) and is currently being tested in the recruitment step for a phase 2 clinical trial to treat prostate, non-small cell lung, and breast cancers (https://clinicaltrials.gov/ct2/show/NCT02538432?term=CJ-023%2C423&rank=2).[13]
- The EP4 selective antagonist, BGC20-1531, is being tested for its ability to block PGE2-induced headaches in health volunteers to determine if it is a potentially useful candidate for testing its effectiveness on clinical headaches (https://clinicaltrials.gov/ct2/show/NCT00957983?term=EP4&rank=1).
- Grapiprant, a highly selective and potent EP4 antagonist, is approved by the Food and Drug Administration for use in canine medicine to treat pain caused by inflammation such as that occurring in osteoarthritis;[22] it is currently also under investigation for use in humans.[23]
Genomic Studies
The GG
Several PTGER4 gene variations have been associated with inflammatory bowel disease: a)
The A/T SNP variant, rs4434423,[31] in the 5'-untranslated region of PTGER4 has been associated with and increase rate of primary graft dysfunction in a multicentered cohort study of graph recipients of different ethnicities.[27]
See also
- Prostaglandin E2 receptor 1 (EP1)
- Prostaglandin E2 receptor 2 (EP2)
- Prostaglandin E2 receptor 3 (EP3)
- Eicosanoid receptor
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000171522 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000039942 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "PTGER3 prostaglandin e receptor 3 [Homo sapiens (Human)] - Gene - NCBI". Archived from the original on 2016-02-26. Retrieved 2017-01-24.
- ^ PMID 21752876.
- ^ "PTGER4 prostaglandin e receptor 4 [Homo sapiens (Human)] - Gene - NCBI". Archived from the original on 2017-02-11. Retrieved 2017-02-06.
- ^ "Entrez Gene: PTGER4 prostaglandin E receptor 4 (subtype EP4)". Archived from the original on 2010-12-05.
- ^ "EP4 receptor - Prostanoid receptors - IUPHAR/BPS Guide to PHARMACOLOGY". www.guidetopharmacology.org. Archived from the original on 2 January 2018. Retrieved 6 May 2018.
- PMID 20948178.
- ^ PMID 27190998.
- S2CID 7766467.
- ^ PMID 27506873.
- ^ S2CID 1513449.
- ^ PMID 22187483.
- ^ PMID 25343148.
- PMID 11001172.
- S2CID 32049750.
- ^ PMID 25179301.
- S2CID 28363263.
- S2CID 23372528.
- S2CID 4170611.
- PMID 28169162.
- ^ snpdev. "Reference SNP (refSNP) Cluster Report: rs10440635". www.ncbi.nlm.nih.gov. Archived from the original on 18 February 2017. Retrieved 6 May 2018.
- PMID 21743469.
- S2CID 25930196.
- ^ PMID 27708579.
- ^ "No items found - Gene - NCBI". www.ncbi.nlm.nih.gov. Archived from the original on 19 February 2017. Retrieved 6 May 2018.
- ^ "No items found - Gene - NCBI". www.ncbi.nlm.nih.gov. Archived from the original on 4 March 2017. Retrieved 6 May 2018.
- ^ "PTGER4 prostaglandin e receptor 4 [Homo sapiens (Human)] - Gene - NCBI". Archived from the original on 2018-05-06. Retrieved 2017-02-19.
- ^ "No items found - Gene - NCBI". www.ncbi.nlm.nih.gov. Archived from the original on 4 March 2017. Retrieved 6 May 2018.
External links
- "Prostanoid Receptors: EP4". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-09.
Further reading
- Duncan AM, Anderson LL, Funk CD, Abramovitz M, Adam M (February 1995). "Chromosomal localization of the human prostanoid receptor gene family". Genomics. 25 (3): 740–2. PMID 7759114.
- Wu H, Wu T, Hua W, Dong X, Gao Y, Zhao X, Chen W, Cao W, Yang Q, Qi J, Zhou J, Wang J (March 2015). "PGE2 receptor agonist misoprostol protects brain against intracerebral hemorrhage in mice". Neurobiology of Aging. 36 (3): 1439–50. PMID 25623334.
- Regan JW, Bailey TJ, Pepperl DJ, Pierce KL, Bogardus AM, Donello JE, Fairbairn CE, Kedzie KM, Woodward DF, Gil DW (August 1994). "Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype". Molecular Pharmacology. 46 (2): 213–20. PMID 8078484.
- Bastien L, Sawyer N, Grygorczyk R, Metters KM, Adam M (April 1994). "Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype". The Journal of Biological Chemistry. 269 (16): 11873–7. PMID 8163486.
- An S, Yang J, Xia M, Goetzl EJ (November 1993). "Cloning and expression of the EP2 subtype of human receptors for prostaglandin E2". Biochemical and Biophysical Research Communications. 197 (1): 263–70. PMID 8250933.
- Foord SM, Marks B, Stolz M, Bufflier E, Fraser NJ, Lee MG (July 1996). "The structure of the prostaglandin EP4 receptor gene and related pseudogenes". Genomics. 35 (1): 182–8. PMID 8661119.
- Fedyk ER, Phipps RP (October 1996). "Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells". Proceedings of the National Academy of Sciences of the United States of America. 93 (20): 10978–83. PMID 8855294.
- Mori K, Tanaka I, Kotani M, Miyaoka F, Sando T, Muro S, Sasaki Y, Nakagawa O, Ogawa Y, Usui T, Ozaki S, Ichikawa A, Narumiya S, Nakao K (June 1996). "Gene expression of the human prostaglandin E receptor EP4 subtype: differential regulation in monocytoid and lymphoid lineage cells by phorbol ester". Journal of Molecular Medicine. 74 (6): 333–6. S2CID 20377539.
- Mukhopadhyay P, Geoghegan TE, Patil RV, Bhattacherjee P, Paterson CA (May 1997). "Detection of EP2, EP4, and FP receptors in human ciliary epithelial and ciliary muscle cells". Biochemical Pharmacology. 53 (9): 1249–55. PMID 9214685.
- Cosme R, Lublin D, Takafuji V, Lynch K, Roche JK (July 2000). "Prostanoids in human colonic mucosa: effects of inflammation on PGE(2) receptor expression". Human Immunology. 61 (7): 684–96. PMID 10880739.
- Desai S, April H, Nwaneshiudu C, Ashby B (December 2000). "Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration". Molecular Pharmacology. 58 (6): 1279–86. PMID 11093764.
- Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, Millar RP, Jabbour HN (May 2001). "Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors". The Journal of Clinical Endocrinology and Metabolism. 86 (5): 2243–9. PMID 11344234.
- Faour WH, He Y, He QW, de Ladurantaye M, Quintero M, Mancini A, Di Battista JA (August 2001). "Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts". The Journal of Biological Chemistry. 276 (34): 31720–31. PMID 11423555.
- Desai S, Ashby B (July 2001). "Agonist-induced internalization and mitogen-activated protein kinase activation of the human prostaglandin EP4 receptor". FEBS Letters. 501 (2–3): 156–60. S2CID 29938003.
- Slipetz D, Buchanan S, Mackereth C, Brewer N, Pellow V, Hao C, Adam M, Abramovitz M, Metters KM (October 2001). "Sequestration and phosphorylation of the prostaglandin E2 EP4 receptor: dependence on the C-terminal tail". Biochemical Pharmacology. 62 (8): 997–1012. S2CID 25415232.
- Fujino H, West KA, Regan JW (January 2002). "Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2". The Journal of Biological Chemistry. 277 (4): 2614–9. PMID 11706038.
- Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimoto Y, Narumiya S, Sugimura T, Wakabayashi K (January 2002). "Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis". Cancer Research. 62 (1): 28–32. PMID 11782353.
- Kvirkvelia N, Vojnovic I, Warner TD, Athie-Morales V, Free P, Rayment N, Chain BM, Rademacher TW, Lund T, Roitt IM, Delves PJ (February 2002). "Placentally derived prostaglandin E2 acts via the EP4 receptor to inhibit IL-2-dependent proliferation of CTLL-2 T cells". Clinical and Experimental Immunology. 127 (2): 263–9. PMID 11876748.
- Asano T, Shoda J, Ueda T, Kawamoto T, Todoroki T, Shimonishi M, Tanabe T, Sugimoto Y, Ichikawa A, Mutoh M, Tanaka N, Miwa M (April 2002). "Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression". Clinical Cancer Research. 8 (4): 1157–67. PMID 11948128.
- Kyveris A, Maruscak E, Senchyna M (March 2002). "Optimization of RNA isolation from human ocular tissues and analysis of prostanoid receptor mRNA expression using RT-PCR". Molecular Vision. 8: 51–8. PMID 11951086.
- Scandella E, Men Y, Gillessen S, Förster R, Groettrup M (August 2002). "Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells". Blood. 100 (4): 1354–61. PMID 12149218.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.